ALNY:NSD-Alnylam Pharmaceuticals, Inc (USD)

COMMON STOCK | Biotechnology | NSD

Last Closing Price

USD 182.41

Change

0.00 (0.00)%

Market Cap

USD 21.44B

Volume

0.51M

Avg Analyst Target

USD 196.44 (+7.69%)

Avg User Target

USD
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

About

Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing RNA interference (RNAi) therapeutics. The company's pipeline of investigational RNAi therapeutics focus on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system (CNS)/ocular diseases. Its marketed products include ONPATTRO (patisiran), a lipid complex injection for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria (AHP); and OXLUMO (lumasiran) for the treatment of primary hyperoxaluria type 1 (PH1). In addition, the company is developing givosiran for the treatment of adolescent patients with AHP; lumasiran for the treatment of advanced PH1 and recurrent renal stones; patisiran for the treatment of transthyretin amyloidosis, or ATTR amyloidosis, with cardiomyopathy; and vutrisiran for the treatment of ATTR amyloidosis. Alnylam Pharmaceuticals, Inc. has strategic collaborations with Regeneron Pharmaceuticals, Inc. to discover, develop, and commercialize RNAi therapeutics for a range of diseases by addressing therapeutic targets expressed in the eye and CNS; and Sanofi Genzyme to discover, develop, and commercialize RNAi therapeutics. It also has license and collaboration agreements with Novartis AG to develop, manufacture, and commercialize RNAi therapeutics for the treatment of proprotein convertase subtilisin/kexin type 9, hypercholesterolemia, and other human diseases; with Vir Biotechnology, Inc. to develop and commercialize RNAi therapeutics to treat SARS-CoV-2, the virus that causes the disease COVID-19; Dicerna Pharmaceuticals, Inc. to develop and commercialize investigational RNAi therapeutics for the treatment of alpha-1 antitrypsin deficiency-associated liver disease; and with Ionis Pharmaceuticals, Inc. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts.

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2021-07-24 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
MRNA Moderna, Inc

N/A

USD140.07B 233.80 177.21
BNTX BioNTech SE

N/A

USD68.10B 51.40 36.74
REGN Regeneron Pharmaceuticals, Inc

N/A

USD62.47B 16.69 13.11
VRTX Vertex Pharmaceuticals Incorpo..

N/A

USD51.90B 19.11 12.98
ALXN Alexion Pharmaceuticals, Inc

N/A

USD40.34B 59.23 42.56
BGNE BeiGene, Ltd

N/A

USD29.28B N/A N/A
GMAB Genmab A/S

N/A

USD29.00B 33.07 3.64
SGEN Seagen Inc

N/A

USD26.42B 40.63 36.19
RPRX Royalty Pharma plc

N/A

USD24.49B 33.25 14.59
IMMU Immunomedics, Inc

N/A

USD20.31B N/A N/A

ETFs Containing ALNY

Symbol Name Weight Mer Price(Change) Market Cap
FBT First Trust NYSE Arca Bio.. 0.00 % 0.55 %

N/A

USD1.96B
BTEC Principal Healthcare Inno.. 0.00 % 0.42 %

N/A

USD0.18B
GNOM Global X Genomics & Biote.. 0.00 % 0.50 %

N/A

USD0.25B
BIGT:LSE Legal & General UCITS ETF.. 0.00 % 0.49 %

N/A

USD0.03B

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 40.35% 83% B 83% B
Dividend Return N/A N/A N/A N/A N/A
Total Return 40.35% 83% B 83% B
Trailing 12 Months  
Capital Gain 19.14% 65% D 39% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 19.14% 65% D 37% F
Trailing 5 Years  
Capital Gain 175.54% 79% C+ 79% C+
Dividend Return N/A N/A N/A N/A N/A
Total Return 175.54% 79% C+ 79% C+
Average Annual (5 Year Horizon)  
Capital Gain 42.56% 72% C- 82% B-
Dividend Return N/A N/A N/A N/A N/A
Total Return 42.56% 72% C- 82% B-
Risk Return Profile  
Volatility (Standard Deviation) 71.60% 43% F 24% F
Risk Adjusted Return 59.45% 85% B 76% C
Market Capitalization 21.44B 98% A+ 95% A
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio N/A N/A N/A N/A N/A
Price/Book Ratio 23.15 7% F 5% F
Price / Cash Flow Ratio -34.87 85% B 84% B
EV/EBITDA N/A N/A N/A N/A N/A
Management Effectiveness  
Return on Equity -77.01% 35% F 22% F
Return on Invested Capital -62.82% 37% F 13% F
Return on Assets -18.17% 66% D 20% F
Debt to Equity Ratio 18.82% 44% F 61% D-
Technical Ratios  
Short Ratio 5.34 35% F 22% F
Short Percent 3.70% 70% C- 46% F
Beta 1.23 57% F 45% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

No discussions yet

User / Independent Analyst Ratings

User Name Target Rating Target Horizon (Months) Target Price User Analysis Date Comment

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Superior Revenue Growth

This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.

What to not like:
High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Highly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector